WEREWOLF THERAPEUTICS, INC. Other Nonoperating Income (Expense)
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Other Nonoperating Income (Expense) of $64.00 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-06-30 was $64.00K, a 481.82% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-03-31 was $674.00K, a 301.19% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-12-31 was $1.84M.
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2023 was -$1.14M, a 437.87% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2022 was $338.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $64.00K S-4 · filed 2026-09-22 | $738.00K S-4 · filed 2026-09-22 | $2.58M derived: sum of 3 quarters · filed 2026-09-22 | $2.58M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $674.00K 10-Q · filed 2026-05-07 | $2.52M derived: sum of 2 quarters · filed 2026-09-22 | $2.52M derived: sum of 3 quarters · filed 2026-09-22 | $2.53M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $1.84M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $1.84M derived: sum of 2 quarters · filed 2026-09-22 | $1.85M derived: sum of 3 quarters · filed 2026-09-22 | $2.02M S-4 · filed 2026-09-22 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $11.00K derived: sum of 2 quarters · filed 2026-09-22 | $179.00K 10-Q · filed 2025-11-04 | $85.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $11.00K S-4 · filed 2026-09-22 | $179.00K S-4 · filed 2026-09-22 | $85.00K derived: sum of 3 quarters · filed 2026-09-22 | $182.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $168.00K 10-Q · filed 2026-05-07 | $74.00K derived: sum of 2 quarters · filed 2026-09-22 | $171.00K derived: sum of 3 quarters · filed 2026-09-22 | $1.78M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$94.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $3.00K derived: sum of 2 quarters · filed 2026-09-22 | $1.62M derived: sum of 3 quarters · filed 2026-09-22 | $1.61M S-4 · filed 2026-09-22 |
| 2024-09-30 | $97.00K 10-Q · filed 2025-11-04 | $1.71M derived: sum of 2 quarters · filed 2025-11-04 | $1.71M 10-Q · filed 2025-11-04 | $1.70M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-14 | $1.61M 10-Q · filed 2025-08-14 | $1.61M derived: sum of 3 quarters · filed 2025-08-14 | $1.60M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.00K 10-Q · filed 2025-05-08 | -$7.00K derived: sum of 2 quarters · filed 2025-05-08 | -$12.00K derived: sum of 3 quarters · filed 2025-05-08 | -$37.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$11.00K derived: sum of 2 quarters · filed 2025-03-11 | -$36.00K derived: sum of 3 quarters · filed 2025-03-11 | -$1.14M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$5.00K 10-Q · filed 2024-11-07 | -$30.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.14M 10-Q · filed 2024-11-07 | -$1.07M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$25.00K 10-Q · filed 2024-08-08 | -$1.13M 10-Q · filed 2024-08-08 | -$1.06M derived: sum of 3 quarters · filed 2024-08-08 | -$1.06M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.11M 10-Q · filed 2024-05-03 | -$1.04M derived: sum of 2 quarters · filed 2024-05-03 | -$1.03M derived: sum of 3 quarters · filed 2024-05-03 | -$752.00K derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $73.00K derived: sum of 2 quarters · filed 2024-03-07 | $354.00K derived: sum of 3 quarters · filed 2024-03-07 | $338.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-14 | $284.00K derived: sum of 2 quarters · filed 2023-11-14 | $268.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $281.00K 10-Q · filed 2023-08-10 | $265.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$16.00K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | -$17.00K 10-Q · filed 2022-11-10 | -$33.00K derived: sum of 2 quarters · filed 2022-11-10 | -$49.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$16.00K 10-Q · filed 2022-08-11 | -$32.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$16.00K 10-Q · filed 2021-06-10 | |||
| 2020-06-30 | -$3.00K 10-Q · filed 2021-08-12 | -$3.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |